In younger patients without age‐related neurodegeneration, serum GFAP levels may be a specific biomarker for NMOSD rather than for MS, while in older patients with advanced neurodegeneration, the specificity of GFAP as a diagnostic marker may be compromised. This evidence concerns the gene GFAP and myeloid sarcoma.